The Food and Drugs Authority (FDA) has approved herbal medicine developed by Kwame Nkrumah University of Science and Technology (KNUST) for clinical trial.
– FDA approves KNUST’s Herbal Medicine for Clinical Trial to investigate treatment of Covid-19.
KNUST submitted a clinical trial application in September 2020 to assess the safety and efficacy of Cryptolepis sanguinolenta as a potential treatment for Covid-19.
After a long series of research, the FDA has finally approved Cryptofepis sanguinolenta, locally known as Nibima for clinical trials.
The herbal medicine developed by KNUST could be a potential vaccine or treatment for Covid-19.
“It is hoped that data from this study may be useful to inform policy or be used for scientific judgments and opinions in relation to COVID-19.” The statement read.
